Selected publication milestones, not an exhaustive history or discovery priority claim.
2001 — A defined perinatal probiotic regimen tests eczema prevention. Original PMID11297958.
2008 — Microbiota and host genotype interact in experimental autoimmune diabetes. Original PMID18806780.
2012 — Neonatal versus adult colonization distinguishes an immune-development window in mice. Original PMID22442383.
2015 — Early microbial taxa link human risk observations with recipient-mouse airway experiments. Original PMID26424567.
2016 — Amish–Hutterite observations combine with contrasting dust perturbations in mice. Original PMID27518660.
2016 — Different bacterial LPS signals link human cohorts with NOD-mouse experiments. Original PMID27133167.
2022 — Daycare biodiversity intervention tests immune and microbiome markers. Original PMID35930838.
2026 — ORBEX reports a null clinical primary outcome after bacterial-lysate treatment. Original PMID42705251.
Microbial quality, amount, route and timing are distinct exposures, not one hygiene variable.
Human autoimmune clinical prevention remains a separate missing causal branch.
Positive eczema effects do not consistently extend to sensitization, food allergy or asthma.
Clinical effects may occur without durable microbial engraftment or diversity change; the mediator needs identification.
Environmental soil interventions need disease-incidence follow-up beyond immune biomarkers.
Shared cohort/trial reports and post-hoc genotype/delivery subgroups require prospective independent validation.
Register microbial-factor/consortium restoration in an objectively baseline-defined infant population, with credible placebo, measured exposure/engagement and immune mediation. Prespecify clinical eczema, asthma and separately powered autoimmune endpoints, retain all randomized participants, and independently replicate dose/window and host-genotype predictions. Include antigen/diet/barrier and infection-indication controls.